Those include Innovent Bio's IBI343 in phase 3, AstraZeneca/Keymed's AZD0901 in phase 2, and a string of earlier-stage candidates from Merck KGaA/Hengrui, Transcenta, I-Mab, BioNTech, Leap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback